Treatment of multiple sclerosis patients with daclizumab, an antibody targeting IL-2Rα (CD25), resulted in an increase in the numbers of NK cells that correlated with drug efficacy [126]. The gene discussed is IL2RA; the disease is multiple sclerosis.